Quang Dinh Tran

Quang Dinh Tran

Auto-generated profile, based on publicly available information

Quang Dinh Tran

A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DGDavid E. Gordon
David E. Gordon
GJGwendolyn M. Jang
Gwendolyn M. Jang
MBMehdi Bouhaddou
Mehdi Bouhaddou
JXJiewei Xu
Jiewei Xu
KOKirsten Obernier
Kirsten Obernier
NKNevan J. Krogan
Nevan J. Krogan

1 August 2020 in Cell
Verified
Journal Article
Closed access
MBMehdi Bouhaddou
Mehdi Bouhaddou
DMDanish Memon
Danish Memon
BMBjoern Meyer
Bjoern Meyer
KWKris White
Kris White
VRVeronica V. Rezelj
Veronica V. Rezelj
NKNevan J. Krogan
Nevan J. Krogan

16 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
VRVeronica V. Rezelj
Veronica V. Rezelj
LCLucía Carrau
Lucía Carrau
FMFernando Merwaiss
Fernando Merwaiss
LLLaura Inès LEVI
Laura Inès LEVI
DEDiana Erazo
Diana Erazo
MMarco Vignuzzi
Marco Vignuzzi
Arthropod-borne viruses pose a major threat to global public health. Thus, innovative strategies for their control and prevention are urgently needed. Here, we exploit the natural capacity of viruses to generate defective viral genomes (DVGs) to their detriment. While DVGs have been described for most viruses, identifying which, if any, can be used as therapeutic agents remains a challenge. We present a combined experimental evolution and computational approach to triage DVG sequence space and pinpoint the fittest deletions, using Zika virus as an arbovirus model. This approach identifies fit DVGs that optimally interfere with wild-type virus infection. We show that the most fit DVGs conserve the open reading frame to maintain the translation of the remaining non-structural proteins, a characteristic that is fundamental across the flavivirus genus. Finally, we demonstrate that the high fitness DVG is antiviral in vivo both in the mammalian host and the mosquito vector, reducing transmission in the latter by up to 90%. Our approach establishes the method to interrogate the DVG fitness landscape, and enables the systematic identification of DVGs that show promise as human therapeutics and vector control strategies to mitigate arbovirus transmission and disease.

17 April 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
CCCélia Caillet-Saguy
Célia Caillet-Saguy
FDFabien Durbesson
Fabien Durbesson
VRVeronica V. Rezelj
Veronica V. Rezelj
GGGergö Gogl
Gergö Gogl
QTQuang Dinh Tran
Quang Dinh Tran
NWNicolas Wolff
Nicolas Wolff
Small linear motifs targeting protein interacting domains called PSD‐95/Dlg/ZO‐1 (PDZ) have been identified at the C terminus of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) proteins E, 3a, and N. Using a high‐throughput approach of affinity‐profiling against the full human PDZome, we identified sixteen human PDZ binders of SARS‐CoV‐2 proteins E, 3A, and N showing significant interactions with dissociation constants values ranging from 3 to 82 μm. Six of them (TJP1, PTPN13, HTRA1, PARD3, MLLT4, LNX2) are also recognized by SARS‐CoV while three (NHERF1, MAST2, RADIL) are specific to SARS‐CoV‐2 E protein. Most of these SARS‐CoV‐2 protein partners are involved in cellular junctions/polarity and could be also linked to evasion mechanisms of the immune responses during viral infection. Among the binders of the SARS‐CoV‐2 proteins E, 3a, or N, seven significantly affect viral replication under knock down gene expression in infected cells. This PDZ profiling identifying human proteins potentially targeted by SARS‐CoV‐2 can help to understand the multifactorial severity of COVID19 and to conceive effective anti‐coronaviral agents for therapeutic purposes.

13 January 2022 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ASAvi J. Samelson
Avi J. Samelson
QTQuang Dinh Tran
Quang Dinh Tran
RRRémy Robinot
Rémy Robinot
LCLucia Carrau
Lucia Carrau
VRVeronica V. Rezelj
Veronica V. Rezelj
MKMartin Kampmann
Martin Kampmann

4 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAlice Mac Kain
Alice Mac Kain
GMGhizlane Maarifi
Ghizlane Maarifi
SASophie-Marie Aicher
Sophie-Marie Aicher
NANathalie Arhel
Nathalie Arhel
ABArtem Baidaliuk
Artem Baidaliuk
FRFerdinand Roesch
Ferdinand Roesch
Interferon restricts SARS-CoV-2 replication in cell culture, but only a handful of Interferon Stimulated Genes with antiviral activity against SARS-CoV-2 have been identified. Here, we describe a functional CRISPR/Cas9 screen aiming at identifying SARS-CoV-2 restriction factors. We identify DAXX, a scaffold protein residing in PML nuclear bodies known to limit the replication of DNA viruses and retroviruses, as a potent inhibitor of SARS-CoV-2 and SARS-CoV replication in human cells. Basal expression of DAXX is sufficient to limit the replication of SARS-CoV-2, and DAXX over-expression further restricts infection. DAXX restricts an early, post-entry step of the SARS-CoV-2 life cycle. DAXX-mediated restriction of SARS-CoV-2 is independent of the SUMOylation pathway but dependent on its D/E domain, also necessary for its protein-folding activity. SARS-CoV-2 infection triggers the re-localization of DAXX to cytoplasmic sites and promotes its degradation. Mechanistically, this process is mediated by the viral papain-like protease (PLpro) and the proteasome. Together, these results demonstrate that DAXX restricts SARS-CoV-2, which in turn has evolved a mechanism to counteract its action.